NCT06615375 - A Human Challenge Study to Assess Protection of a Shigella Tetravalent Bioconjugate Vaccine | Biotech Hunter

Enrollment

120

Participants

Timeline

Start Date

November 12, 2024

Primary Completion Date

February 28, 2026

Study Completion Date

July 31, 2026

Conditions

Shigellosis

Interventions

BIOLOGICAL

Shigella4V2

Shigella4V2 is a tetravalent bioconjugate vaccine

BIOLOGICAL

Placebo

Phosphate-buffered saline

Trial Locations (3)

RECRUITING

Johns Hopkins Center for Immunization Research, Baltimore

COMPLETED

Hope Clinic of Emory University, Atlanta

RECRUITING

Cincinnati Children's Hospital Medical Center, Cincinnati